ACA
JAZZ icon

Atlas Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Atlas Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$959K Buy
5,074
+1,967
+63% +$344K 0.11% 157
2025
Q4 		$528K Buy
+3,107
New +$476K 0.06% 247
2025
Q2 		$32.4K Sell
305
-4,309
-93% -$468K ﹤0.01% 672
2025
Q1 		$573K Buy
4,614
+4,302
+1,379% +$561K 0.07% 228
2024
Q4 		$38.4K Buy
+312
New +$36.8K ﹤0.01% 650

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Atlas Capital Advisors's JAZZ Position: Q1 2026 in Review

Atlas Capital Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 63% in Q1 2026, buying an estimated $344K and bringing the position to 5,074 shares worth $959K. The position accounts for 0.11% of the portfolio, ranked #157.

Atlas Capital Advisors first reported a position in JAZZ in Q4 2024 and has held it in 5 quarters since. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Atlas Capital Advisors held 5,074 shares of Jazz Pharmaceuticals worth $959K as of Q1 2026.
  • Atlas Capital Advisors bought 1,967 Jazz Pharmaceuticals shares in Q1 2026, an estimated $344K.
  • Jazz Pharmaceuticals made up 0.11% of Atlas Capital Advisors's portfolio in Q1 2026, its #157 holding.
  • Atlas Capital Advisors first reported a position in Jazz Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • 571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Atlas Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.